Clear answers about eligibility, pricing, shipping, and how ongoing care works with Momentum Health 360
For the full BPC-157 dosing breakdown, see our BPC-157 dosage protocol guide: BPC-157: 200 to 500 mcg per day, subcutaneous injection near the injury site, 4 to 8 weeks TB-500 loading phase (Weeks 1-4): 2 to 5 mg twice per week TB-500 maintenance phase (Weeks 5-8): 2 mg once per week Route: Both peptides are administered via subcutaneous injection
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
Kiyoshi Okada, Hiroyuki Tanaka, Ko Temporin, Michio Okamoto, Yusuke Kuroda, Hisao Moritomo, Tsuyoshi Murase, Hideki Yoshikawa, Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model, Experimental Neurology, Volume 222, Issue 2, April 2010, Pages 191-203 Tanaka, H
Remember: 1mg = 1,000mcg
However, pharmacokinetic studies have shown methylcobalamin stays longer in brain and liver tissues
